ST-segment-elevation MI (STEMI) is associated with increased mortality and morbidity. 1 Primary percutaneous coronary intervention (PPCI) in conjunction with rapid, potent antithrombotic therapy has resulted in reduced rates of recurrent ischemic events and significantly improved outcomes of patients with STEMI. 2-5 Unfortunately, reductions in recurrent ischemic events were coupled by an increase in iatrogenic hemorrhagic complications. 4,6 Major bleeding after STEMI has been associated with increased short-term mortality as well as long-term mortality. 7,8 The short-term mortality hazard of bleeding may be explained by the direct fatal course of intracranial or retroperitoneal bleedings. 9,10 However, the mechanisms by which major bleeding affects mortality long after the bleeding event are more elusive. Coagulation and platelet activation in response to anemia, the adverse effects of blood transfusions and premature cessation of antithrombotic therapy, have been proposed as mechanisms responsible for the long-term adverse effects of bleeding. 11, 12 However, in some studies, bleeding was associated with short-term mortality, but not long-term mortality, and it has been postulated that unmeasured comorbidity accounted for the higher mortality observed in some studies in patients with bleeding. 13, 14 Consequently, the prognostic value of bleeding complications for long-term mortality is currently subject to debate. Thus, gaining more insight into how mortality is affected in time after the bleeding and recurrent MI might shed light on the mechanisms responsible for the relationship between bleeding Background-The prognosis of initial survivors of ST-segment-elevation myocardial infarction (STEMI) is affected by both recurrent myocardial infarction (MI) and severe bleeding. The aim of the current study was to investigate how mortality is affected in time after bleeding and recurrent MI.
and subsequent mortality. Therefore, the aims of the present analysis are the following: (1) to investigate the relative prognostic value of recurrent MI and severe bleeding on subsequent mortality; (2) to investigate how mortality is affected in time after bleeding and recurrent MI.
Methods

Source Population and Procedures
The data analyzed in this study were obtained from patients with STEMI who were accepted for PPCI at the Academic Medical Center-University of Amsterdam between January 1, 2003, and July 31, 2008 . The study complied with the Declaration of Helsinki and was approved by the local ethics committee. In general, patients qualified for PPCI if they had typical ischemic chest pain and ≥1-mm ST-segment-elevation in ≥2 contiguous leads, a new left bundle-branch block, or a true posterior MI. Patients received a standard 300 to 600 mg loading dose clopidogrel. If a coronary stent was implanted, clopidogrel was prescribed for ≥1 month to patients with a bare-metal stent and for 6 to 12 months to patients with a drug-eluting stent. Patients were routinely pretreated with 300 mg aspirin and 5000 IU unfractionated heparin. An additional heparin bolus was administered at the catheterization laboratory if necessary to achieve a targeted activated clotting time of 300 seconds followed by an infusion of 12 U/kg per hour with titration to achieve a target activated partial thromboplastin time of 1.5 to 2.0 times the control. Glycoprotein IIb/IIIa inhibitors were used at the discretion of the operator.
Procedural and angiographic data were prospectively collected and entered by interventional cardiologists and specialized nurses. Chart review for consecutive patients with STEMI with available activated partial thromboplastin time measurements was performed in the context of a study designed to investigate the relationship between activated partial thromboplastin time and clinical outcome in patients with STEMI treated with PPCI. A detailed description of the study protocol has been previously published. 15 We obtained clinical history, detailed information on periprocedural treatment, and follow-up of clinical outcome by reviewing inpatient and outpatient charts in the PCI center and referring hospitals. For every patient, we systematically checked inpatient charts of every hospital admission for the occurrence of recurrent MI and bleeding. For the present analysis, follow-up for recurrent MI and bleeding was censored at the date of death or at 1 year after the index PCI, whichever came first. Patients whose whereabouts could not be traced were considered lost to follow-up from the date of last known medical contact. Follow-up information about vital status was obtained from computerized, long-term mortality records from the National Death Index between January 1, 2012, and April 30, 2012. If a patient could not be identified in these records (eg, foreign patients), censoring was at the date of last contact. Follow-up for mortality was censored at the actual date of ascertainment of vital status in the National Death Index or at 4 years after the index PCI, whichever came first.
Study Design
The study cohort consisted of all patients with STEMI included in our study database, who were alive at the end of the procedure. Primary outcome for the present analysis was all-cause mortality within 4 years after PPCI. A bleeding was considered to have occurred when the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) severe bleeding criteria were met. 16 In secondary analyses, a bleeding was considered to have occurred if it met the Thrombolysis In Myocardial Infarction (TIMI) major bleeding criteria. 17 Recurrent MI was defined according to the Academic Research Consortium criteria. 18 Revascularization-related MIs were not considered recurrent MIs in the current study. In case a patient had multiple recurrent MIs or multiple severe bleedings, only the first recurrent MI or bleeding was taken into consideration.
Statistical Analysis
Event rates of recurrent MI and bleeding within 1 year were estimated using Kaplan-Meier analyses. Baseline predictors of 4-year mortality were identified by performing a stepwise backward selection Cox regression analysis. Entry criterion was set at P<0.05, and exit criterion was set at P=0. 10 . The predictive discrimination of the model was assessed by calculating Harrell C index. 19 To investigate the relationship between the occurrence of recurrent MI or GUSTO severe bleeding and subsequent mortality, we first performed Cox regression analysis with each adverse event separately as time-dependent covariate. Next, to investigate the relative impact of bleeding and recurrent MI on 4-year mortality, we developed a Cox regression model with each adverse event simultaneously as time-dependent covariate, adjusting for baseline predictors of 4-year mortality. Next, we investigated whether the risk implication of a bleeding or recurrent MI for subsequent mortality abated over time. For this purpose, we calculated hazard ratios (HRs) for mortality after recurrent MI or bleeding for the following time intervals after the event: 0 to 1 day, 2 to 365 days, and >1 year after recurrent MI and 0 to 1 day, 2 to 30 days, and >30 days after bleeding. For each of these time intervals, a binary covariate was entered into a Cox regression model as time-dependent covariate, as previously used by Mehran et al 20 and Pocock et al. 21 The eventual model was again adjusted for baseline predictors of mortality. We also developed a Cox regression model, in which the HR for subsequent mortality was calculated as a decreasing exponential function of the time elapsed (TEL) after the event. In this model, the hazard λ(t|Z,X(t), TEL(t)) at time t in the multivariate Cox proportional hazards model with time-dependent covariates was defined as
with λ 0 (t) representing an unspecified baseline hazard function at time t; X(t) representing a patients' recurrent MI and bleeding status at time t (0 indicating that a patient did not have the adverse event; 1 indicating that a patient had the adverse event), their interaction with TEL, and follow-up time; and the vector Z=(z1, z2, …,zp) of the p fixed covariates available at the time of PPCI. The regression coefficient β represents the effect of the time-fixed covariate Z on the logarithm of the hazard, and the regression coefficient η represents the effect of the time-varying covariates X(t). All significant factors from the multivariate analysis with time-fixed covariates were included
WHAT IS KNOWN
• Recurrent myocardial infarction (MI) and major bleeding complications after ST-segment-elevation MI are associated with increased mortality and morbidity.
• However, the long-term mortality risk of major bleeding complications after ST-segment-elevation MI is currently subject to debate.
• Moreover, the mechanisms by which major bleeding complications affect long-term mortality are unclear.
WHAT THE STUDY ADDS
• The present study shows that both recurrent MI and major bleeding are associated with an immediate increase in mortality shortly after the MI or bleeding.
• The risk of death slowly decreases after recurrent MI and remains elevated long after the MI, whereas after bleeding, the risk of death rapidly decreases and is no longer increased beyond one month after the bleeding event.
in Z. The shape of the G(.)-and H(.)-functions of TEL(t) were allowed to be different and were determined by trial and error until the goodness-of-fit of the model was maximal. 22 All of the above analyses were repeated including TIMI major bleeding as time-dependent covariate instead of GUSTO severe bleeding. Finally, as a sensitivity analysis, we additionally performed the analyses in patients without cardiogenic shock. Data were complete for all outcomes and for 19 out of 40 variables. Missing patient-level covariates were assumed to be missing at random and were imputed with the use of multiple imputations (10×). The imputation procedure and subsequent Cox proportional hazards regression estimation were performed according to Rubin's protocol. 23 Analyses were performed with Statistical Package for Social Sciences software (SPSS version 19.0, Chicago, IL) and R (R Foundation for Statistical Computing, Vienna, Austria).
Results
Of the 2009 patients with STEMI recorded in our database between January 1, 2003, and July 31, 2008, 7 patients died during the index PPCI. Baseline, procedural, and angiographic characteristics of the remaining 2002 patients included in the present analysis are presented in Tables 1 and 2 Table 3 shows the impact of a GUSTO severe bleeding and recurrent MI on the incidence and timing of subsequent 4-year mortality. In a multivariable Cox proportional hazards model including recurrent MI and bleeding as time-dependent covariates adjusting for the previously identified baseline predictors of 4-year mortality, recurrent MI was associated with a 4-fold increase in subsequent 4-year mortality, whereas GUSTO severe bleeding was not associated with higher 4-year mortality. The bottom panel of Table 3 demonstrates the temporal mortality pattern after the occurrence of recurrent MI and bleeding. The likelihood of mortality was 14-fold in the first day after a recurrent MI. Thereafter, the risk of mortality gradually decreased, but remained elevated long after the recurrent MI. The mortality pattern after a GUSTO severe bleeding was different to that after recurrent MI. The risk of mortality was highest in the first day after a GUSTO severe bleeding. However, thereafter the risk of mortality rapidly decreased and, beyond 1 month after the bleeding, the risk of mortality was no longer elevated compared with patients not yet having a bleeding. Figure 1 is the result of a Cox proportional hazards model in which the HR for subsequent mortality was calculated as an exponential function of the TEL after bleeding or recurrent MI. Similar to that in Table 3 , the risk of subsequent mortality was the highest in the days after bleeding or recurrent MI, and gradually decreased after a recurrent MI, but rapidly decreased after a severe bleeding. The HR for mortality remained elevated long after the recurrent MI, but decreased to 1 soon after the bleeding. Table 4 and Figure 2 illustrate the temporal decline in HR for mortality after TIMI major bleeding and recurrent MI. The decline in HR after a TIMI major bleeding resembled the decline in HR after a GUSTO severe bleeding. Tables III and IV in the online-only Data Supplement demonstrate the temporal mortality pattern after recurrent MI, GUSTO severe, and TIMI major bleeding in patients without cardiogenic shock. The results were similar to the results in the complete cohort.
Impact of Bleeding and Recurrent MI on the Incidence and Timing of Subsequent Mortality
Discussion
The main findings of this study can be summarized as follows. The temporal mortality pattern was different for recurrent MI and bleeding. Recurrent MI is followed by a dramatic increase in risk of subsequent mortality on the first day after the recurrent event. Thereafter, the risk of mortality gradually decreases but remains elevated long after recurrent MI. By contrast, the risk of mortality rapidly decreases after a GUSTO severe bleeding; such that after 1 month the risk of mortality is similar to patients without a GUSTO severe bleeding. The temporal mortality pattern after bleeding is irrespective of the applied bleeding definition. Several biological plausible mechanisms may account for the temporal mortality pattern after recurrent MI. Recurrent MI is characterized by myocardial necrosis attributable to ischemia, which can result in direct loss of ventricular function with resultant hemodynamic compromise or heart failure and end-organ hypoperfusion, and fatal arrhythmia attributable to altered electrophysiological properties of ischemic myocardium. 24, 25 These effects of myocardial necrosis are likely to have a direct and immediate effect. In the long term, myocardial necrosis results in myocardial scarring, which contributes to loss of ventricular function, remodeling with secondary valve insufficiencies, heart failure, and late fatal arrhythmias secondary to re-entry circuits in the scarred myocardium. 26, 27 This is consistent with our finding that the risk of subsequent mortality remained elevated long after the recurrent MI in patients having a recurrent MI.
In the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2), Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials, MI was associated with a direct early risk of mortality followed by a subsequent decline in risk of mortality, such that the risk of mortality was no longer elevated beyond 30 days after the MI. 20, 21, 28 By contrast, in the present analysis, recurrent MI remained associated with mortality long after the recurrent event. A possible explanation for the difference between our study and the previous analyses in the REPLACE-2, ACUITY, and HORIZONS-AMI could be that the definition of an MI in these studies included both spontaneous MIs as well as procedure-related MIs. 20, 21 In fact, a large proportion of the MIs in ACUITY were procedure related. 29 Procedure-related MIs were shown in several studies, including ACUITY, to have no significant impact on mortality after multivariable adjustment. 29, 30 Thus, inclusion of procedurerelated MIs in these analyses may have mitigated the longterm prognostic value of spontaneous MIs. 29 In the present analysis, bleeding was associated with a shortterm increase in subsequent mortality. This is in contrast to findings of the REPLACE-2, ACUITY, and HORIZONS-AMI trials, in which the mortality risk of major bleeding was more sustained. 20, 21, 28 Conversely, our findings are in concert with the Global Registry of Acute Coronary Events (GRACE), in which major bleeding was associated with in-hospital mortality but not with mortality occurring after discharge up until 6 months follow-up. 13 Moreover, in the ExTRACT-TIMI-25 trial, nonintracranial TIMI major and minor bleeding were not associated with 30-day and 1-year mortality. 14 Finally, in a meta-analysis including 25 studies in acute coronary syndrome patients, the prognostic value of major bleeding was restricted to in-hospital and 30-day mortality. 31 Thus, our study adds to a growing body of evidence showing that bleeding complications after STEMI are not associated with long-term mortality.
Numerous mechanisms may account for the early, shortterm hazard for mortality after bleeding. Bleeding events can have a direct fatal impact when located intracranially, hemopericardially, or in the retroperitoneal cavity. 14 Severe blood loss associated with major bleeding may result in hemodynamic compromise, which in turn impairs adequate oxygen delivery to vital end organs such as the brain, kidneys, gastrointestinal tract and the myocardium. In patients, whose cardiac output is already impaired, this can further decrease cardiac output and contribute to cardiac death. Other postulated mechanisms by which bleeding may lead to recurrent ischemic events and death include premature cessation of antiplatelet therapy in response to bleeding, 32 platelet and coagulation activation associated with anemia, 11 and the adverse effects of blood transfusions required for correction of severe blood loss. 33 For patients who had a GUSTO severe bleeding, the hazard ratio for death is the highest in the first days after the bleeding and rapidly decreases thereafter. After ≈2 months, the hazard ratio approaches 1, implying that the hazard of subsequent mortality is comparable with that of the control. The hazard ratio for subsequent mortality is the highest in the days after recurrent MI and thereafter gradually decreases but remains elevated long after the recurrent MI. Top, The decline in hazard ratio as an exponential function of time in the first 3 months. Bottom, The decline in hazard ratio for the first 3 years after the event.
Dashed lines represent 95% confidence intervals.
Limitations
There are several potential limitations to our study. First, the patients included in the present analysis were selected from a series of consecutive patients with STEMI on the basis of the availability of ≥1 activated partial thromboplastin time measurement. However, there was no difference in 1-and 4-year all-cause mortality between patients included and excluded in the current study. Moreover, the characteristics of the studied cohort were representative of a typical unselected European STEMI cohort. Therefore, it is unlikely that the selection of patients affected the general conclusion of our study. The hazard ratio for subsequent mortality after TIMI major bleeding followed the same decline as GUSTO severe bleeding (Figure 1) . Top, The decline in hazard ratio as an exponential function of time in the first 3 months. Bottom, The decline in hazard ratio for the first 3 years after the event. Dashed lines represent 95% confidence intervals. Tables 3 and 4 are identical, with the exception of the bleeding time-dependent covariate, which differs in definition, and hence in number of subjects meeting the definition. The prognostic value of recurrent MI in Table 4 is therefore slightly different from the prognostic value of recurrent MI in Table 3 .
Second, although we used multivariable modeling to adjust for baseline differences, it is possible that unmeasured confounders may have affected the relationship between recurrent MI, bleeding, and subsequent mortality. However, we demonstrated in time-dependent Cox models that the occurrence of recurrent MI and bleeding was followed by an immediate and strong increase in risk of subsequent mortality. Therefore, the occurrence of recurrent MI and bleeding and subsequent mortality should be considered strong independent determinants of subsequent mortality.
Conclusions
Our study demonstrates that both recurrent MI and GUSTO severe bleeding have important risk implications for subsequent mortality in patients with STEMI. Recurrent MI is associated with a dramatic early mortality hazard shortly after the recurrent MI. Thereafter the risk of subsequent mortality gradually decreases but remains elevated long after the recurrent MI. By contrast, the risk of subsequent mortality after severe bleeding is confined to the first month after the event. After PPCI, a careful consideration of an individual patient's risk of both events should be made to further optimize treatment of patients with STEMI.
